Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes : a randomized clinical trial. / Skov, J.; Pedersen, M.; Holst, Jens Juul; Madsen, B; Goetze, Jens P; Rittig, S.; Jonassen, Thomas; Frøkiær, J; Dejgaard, A.; Christiansen, J. S.
I: Diabetes, Obesity and Metabolism Online, Bind 18, Nr. 6, 22.02.2016, s. 581-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes
T2 - a randomized clinical trial
AU - Skov, J.
AU - Pedersen, M.
AU - Holst, Jens Juul
AU - Madsen, B
AU - Goetze, Jens P
AU - Rittig, S.
AU - Jonassen, Thomas
AU - Frøkiær, J
AU - Dejgaard, A.
AU - Christiansen, J. S.
N1 - This article is protected by copyright. All rights reserved.
PY - 2016/2/22
Y1 - 2016/2/22
N2 - AIMS: To investigate the effects of a single dose of 1.2 mg liraglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, on key renal parameters in patients with type 2 diabetes.METHODS: The study was a placebo-controlled, double-blind, cross-over in 11 male patients with type 2 diabetes. Measurements included (51) Cr-EDTA plasma clearance estimated glomerular filtration rate (GFR) and MRI-based renal blood flow (RBF), tissue perfusion and - oxygenation.RESULTS: Liraglutide had no effect on GFR (95% CI -6.8 to 3.6 ml/min/1.73 m(2) ) or RBF (95% CI -39 to 30 ml/min) and did not change local renal blood perfusion or oxygenation. The fractional excretion of lithium increased 14% (p = 0.01) and sodium clearance tended to increase (p = 0.06). Liraglutide increased diastolic and systolic blood pressure (3 and 6 mm Hg) and heart rate (3 min(-1) ) (all p < 0.05). Angiotensin II concentration decreased 21% (p = 0.02), but there were no effects on other renin-angiotensin system components, atrial natriuretic peptides (ANP), methanephrines or the excretion of catecholamines.CONCLUSIONS: Short-term liraglutide treatment did not affect renal hemodynamics but decreased the proximal tubular sodium reabsorption. Blood pressure increased as opposed to long-term treatment. Catecholamine levels were unchanged and the results did not support a GLP-1-ANP axis. Angiotensin II levels decreased, which may contribute to renal protection by GLP-1 receptor agonists.
AB - AIMS: To investigate the effects of a single dose of 1.2 mg liraglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, on key renal parameters in patients with type 2 diabetes.METHODS: The study was a placebo-controlled, double-blind, cross-over in 11 male patients with type 2 diabetes. Measurements included (51) Cr-EDTA plasma clearance estimated glomerular filtration rate (GFR) and MRI-based renal blood flow (RBF), tissue perfusion and - oxygenation.RESULTS: Liraglutide had no effect on GFR (95% CI -6.8 to 3.6 ml/min/1.73 m(2) ) or RBF (95% CI -39 to 30 ml/min) and did not change local renal blood perfusion or oxygenation. The fractional excretion of lithium increased 14% (p = 0.01) and sodium clearance tended to increase (p = 0.06). Liraglutide increased diastolic and systolic blood pressure (3 and 6 mm Hg) and heart rate (3 min(-1) ) (all p < 0.05). Angiotensin II concentration decreased 21% (p = 0.02), but there were no effects on other renin-angiotensin system components, atrial natriuretic peptides (ANP), methanephrines or the excretion of catecholamines.CONCLUSIONS: Short-term liraglutide treatment did not affect renal hemodynamics but decreased the proximal tubular sodium reabsorption. Blood pressure increased as opposed to long-term treatment. Catecholamine levels were unchanged and the results did not support a GLP-1-ANP axis. Angiotensin II levels decreased, which may contribute to renal protection by GLP-1 receptor agonists.
U2 - 10.1111/dom.12651
DO - 10.1111/dom.12651
M3 - Journal article
C2 - 26910107
VL - 18
SP - 581
EP - 589
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 6
ER -
ID: 159744015